Fig. 4

Immunogenicity of NSCs. a Fractions of CD107a/b-positive cytotoxic T-lymphocytes (CD3+, CD8+), T-helper lymphocytes (CD3+, CD4+), and natural killer cells (CD56+, CD3− and CD56+, CD3+) in response to NSC exposure. The City of Hope Clinical Immunobiology Correlative Studies Laboratory obtained whole blood from normal human donors (n = 7), isolated PBMCs via Ficoll density gradient centrifugation, then co-cultured them with NSCs in the presence of antibodies against CD107a/b. Positive control PBMCs were exposed to PMA and PHA. After a 5-h incubation period, flow cytometry was performed, with compensation for non-viable cells and isotype controls. b Flow cytometric quantification of PD-L1- and CD47-positive NSCs. c Pooled weights of macroscopic OVCAR8 tumors, as well as their associated stroma, in n = 6 nude mice after three weekly rounds of 2 × 10⁷ NSCs given 2×/week (for a combined total of 12 × 10⁷ NSCs). Treatment started after 1 week or 3 weeks after tumor cell inoculation to evaluate early- and late-stage tumors, respectively